Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00738361 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
A Phase 2 study of Intraocular Melanoma, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT00738361: Completed Phase 2 study of Intraocular Melanoma, sponsored by Ohio State University Comprehensive Cancer Center.
NCT00738361 is a Phase 2 study of Intraocular Melanoma that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 4 participants, below the 82-participant average among 3 other Intraocular Melanoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00738361, a Phase 2 study of Intraocular Melanoma, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with metastatic melanoma of the eye that cannot be removed by surgery.
Primary Outcome
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Conditions Studied
Interventions
- DRUG nab-paclitaxel
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2008-08 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
What the finished NCT00738361 record still lists
NCT00738361 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 82-participant average among 3 other Intraocular Melanoma trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Intraocular Melanoma appearing as the primary indexed condition, and to 1 intervention - of which nab-paclitaxel is the first listed.
NCT00738361 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00738361 about?
NCT00738361 is a clinical study titled "Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery". RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabil...
What is the current status of trial NCT00738361?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2008-08. Estimated completion is 2013-04.
What conditions does trial NCT00738361 study?
This clinical trial studies the following conditions: Intraocular Melanoma.
What interventions are being tested in trial NCT00738361?
The interventions under investigation include: nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00738361?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00738361 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intraocular Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
COMPLETED · Phase 2
-
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
COMPLETED · Phase 2
-
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye
COMPLETED
-
Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia